Allakos Inc. ALLK
0.33 0.00 (+0.00%)
At closeMay 15, 2025, 4:00 PM EDT
0.3291 Day range 0.3291
52-week range unavailable
- YTD
- -72.80%
- 1 year
- -72.34%
- Market cap
- 113.47M
- Shares out
- 89.34M
- Forward P/E
- -2.02
- YTD return
- -72.80%
- 1-year return
- -72.34%
- Volume
- 1.31M
- Open
- 0.3291
- Previous close
- 0.3291
- Day's range
- 0.3291 – 0.3291
- Beta
- 1.02
- Analysts
- Hold
- Price target
- 3.35 (+917.9%)
- Earnings date
- Aug 7, 2024
2Y -4.4109 (-93.06%)
Key statistics
- Enterprise value
- 53.50M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -53.34M
- Total cash
- 92.72M
- Total debt
- 39.00M
- Return on equity
- -121.68%
- Short % of float
- 1.59%
- 50-day average
- 1.10
- 200-day average
- 1.00
Analyst view
Consensus: hold
Hold
Price target (mean) 3.35 +917.9% upside
Now 0.3291
- Target (low)
- 1.40
- Target (mean)
- 3.35
- Target (high)
- 7.00
Ratings (0m) 7 2 buy · 5 hold · 0 sell
- Strong buy2
- Buy0
- Hold5
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.1775.
Financials — quick view
ALLK Revenue — quarterly 0
ALLK Net income — quarterly -26.18M
ALLK EPS — quarterly -0.29
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.22 | -0.21 | +0.01 | +4.55% |
| Aug 7, 2024 | Jun 1, 2024 | -0.32 | -0.30 | +0.02 | +6.25% |
| Aug 7, 2024 | Jun 1, 2024 | -0.32 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.41 | -0.50 | -0.09 | -21.95% |
| May 9, 2024 | Mar 1, 2024 | -0.41 | — | — | — |
| Mar 14, 2024 | Dec 1, 2023 | -0.53 | -0.71 | -0.18 | -33.96% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 26, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jul 18, 2024 | Jefferies | main | Hold | Hold |
| Jun 26, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jun 20, 2024 | Cantor Fitzgerald | reit | — | Neutral |
| Jan 17, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Jan 17, 2024 | Barclays | main | Underweight | Underweight |
About Allakos Inc.
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- allakos.com
News
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc. - ALLK 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders 
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders 
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share 
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results 
Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline 
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Why Is Allakos Stock Plunging On Monday?
Your note
Sign in to keep a note on ALLK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALEXANDER ROBERT ALLEN | Chief Executive Officer | Stock Award(Grant) | Jan 5, 2023 | 1,376,990 |
| PATERSON CRAIG A. | Officer | Stock Award(Grant) | Jan 5, 2023 | 372,474 |
| RADFORD HARLAN BAIRD III | Chief Financial Officer | Sale | Jun 27, 2024 | 204,390 |
| TOMASI ADAM | President | Stock Award(Grant) | Jan 5, 2023 | 748,687 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 18.53% | 16,552,417 | 21.02M | Sep 29, 2024 |
| NEA Management Company, LLC | 6.88% | 6,147,260 | 7.81M | Sep 29, 2024 |
| FMR, LLC | 6.01% | 5,370,247 | 6.82M | Sep 29, 2024 |
| Deep Track Capital, Lp | 5.60% | 5,000,000 | 6.35M | Sep 29, 2024 |
| Vanguard Group Inc | 3.93% | 3,514,345 | 4.46M | Sep 29, 2024 |
| Redmile Group, LLC | 3.44% | 3,077,828 | 3.91M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Advisor Biotechnology Fund | 5.44% | 4,856,700 | 6.17M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.62% | 2,340,161 | 2.97M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.13% | 1,009,952 | 1.28M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 433,254 | 550.23K | Oct 30, 2024 |
| Fidelity Enhanced Small Cap ETF | 0.38% | 338,198 | 429.51K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.20% | 180,630 | 229.40K | Oct 30, 2024 |